Victoria Villaflor, MD joins UCI Health to share key insights from the 2025 ASCO Annual Meeting - Summary - MDSpire
Advertisement
Victoria Villaflor, MD joins UCI Health to share key insights from the 2025 ASCO Annual Meeting
Victoria Villaflor, MD, a recent addition to the UCI Health Chao Family Comprehensive Cancer Center faculty, highlights pivotal findings from ASCO 2025.
To discuss the latest advances in cancer research, particularly in head and neck oncology, and their implications for patient care at UCI Health.
Key Findings:
NIVOPOSTOP trial demonstrated a 10% improvement in recurrence-free survival with nivolumab, statistically significant.
Keynote 689 trial showed promising results in event-free survival with pembrolizumab, but further details on significance are needed.
Cemiplimab in the postoperative setting showed significant event-free survival improvement.
Interpretation:
The findings from these trials suggest a potential shift in the standard of care for head and neck cancers, emphasizing the role of immunotherapy and the need for further research on optimal treatment sequencing.
Limitations:
Further research is needed to determine the optimal sequencing of immunotherapy, as some studies did not achieve statistically significant improvements.
Conclusion:
The advancements in immunotherapy presented at ASCO 2025 may lead to practice-changing therapies in head and neck oncology, particularly with the promising results from the NIVOPOSTOP and Keynote 689 trials.
